{"id":604,"date":"2026-03-02T14:24:51","date_gmt":"2026-03-02T14:24:51","guid":{"rendered":"https:\/\/efanet.org\/annual-report\/?page_id=604"},"modified":"2026-03-06T13:40:08","modified_gmt":"2026-03-06T13:40:08","slug":"transparency-acknowledgements","status":"publish","type":"page","link":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/","title":{"rendered":"Transparency & Acknowledgements"},"content":{"rendered":"\n

EFA\u2019s total funding for 2022 was 1.023.846,19 EUR Euros: 90.89% was from corporate sources (unrestricted core- and project grants and honoraria for advisers) and 9.11% from non-corporate sources (membership fees and EU project grants). The highest contribution from a single source is 19,32%, amounting to the 197,786 Euros received from Chiesi Farmaceutici for the operating and the project programmes.<\/p>\n\n\n\n
Operating programme<\/td>Amount<\/td>% on category <\/td>% on total income <\/td><\/tr>
Grants\u00a0<\/td>335.000,00<\/td> <\/td> <\/td><\/tr>
 <\/td>Abbvie<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Astra Zeneca<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Boehringer Ingelheim<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Chiesi<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>DBV Technologies<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>LEO Pharma<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Novartis<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>OM Vifor Pharma<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Pfizer<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Regeneron<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Roche<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Sanofi Genzyme<\/td>30.000,00<\/td>8,96%<\/td>2,93%<\/td><\/tr>
 <\/td>Viatris*<\/td>5.000,00<\/td>1,49%<\/td>0,49%<\/td><\/tr>
Honoraria for Advisors<\/td>3.750,00<\/td> <\/td> <\/td><\/tr>
 <\/td>Honoraria for advisors<\/td>3.750,00<\/td> <\/td>0,37%<\/td><\/tr>
Membership fees<\/td>14.500,00<\/td> <\/td> <\/td><\/tr>
 <\/td>Membership fees<\/td>14.500,00<\/td> <\/td>1,42%<\/td><\/tr>
 <\/td> <\/td> <\/td> <\/td> <\/td><\/tr>
Deferred income 2022 for 2023 EFA Core activities<\/em><\/td>-236.655,00<\/em><\/td><\/tr><\/tbody><\/table>\n\n\n\n
Project programme<\/td>Amount<\/td>% on category <\/td>% on total income <\/td><\/tr>
EFA projects<\/td>777.663,20<\/td> <\/td> <\/td><\/tr>
 <\/td>Atopic Eczema Consensus Europe – AbbVie<\/td>65.368,75<\/td>8,41%<\/td>6,38%<\/td><\/tr>
 <\/td>Atopic Eczema Consensus Europe – Sanofi\/Regeneron<\/td>65.368,75<\/td>8,41%<\/td>6,38%<\/td><\/tr>
 <\/td>Atopic Eczema Consensus Europe – deferred income from 2021<\/td>26.105,77<\/td>3,36%<\/td>2,55%<\/td><\/tr>
 <\/td>BREATHE Coalition – Astra Zeneca<\/td>48.431,00<\/td>6,23%<\/td>4,73%<\/td><\/tr>
 <\/td>BREATHE Coalition – Boehringer Ingelheim<\/td>48.431,00<\/td>6,23%<\/td>4,73%<\/td><\/tr>
 <\/td>BREATHE Coalition – Chiesi<\/td>48.431,00<\/td>6,23%<\/td>4,73%<\/td><\/tr>
 <\/td>BREATHE Coalition – Roche<\/td>48.431,00<\/td>6,23%<\/td>4,73%<\/td><\/tr>
 <\/td>BREATHE Coalition – deferred income from 2021<\/td>39.712,10<\/td>5,11%<\/td>3,88%<\/td><\/tr>
 <\/td>Capacity Building – Astra Zeneca<\/td>44.565,00<\/td>5,73%<\/td>4,35%<\/td><\/tr>
 <\/td>Capacity Building – Chiesi<\/td>44.564,67<\/td>5,14%<\/td>4,35%<\/td><\/tr>
 <\/td>Capacity Building – Novartis<\/td>40.000,00<\/td>5,14%<\/td>3,91%<\/td><\/tr>
 <\/td>Capacity Building Deferred income from 2021<\/td>4.500,00<\/td>0,58%<\/td>0,44%<\/td><\/tr>
 <\/td>DIG_IT 2.0 – Chiesi<\/td>32.257,00<\/td>4,15%<\/td>3,15%<\/td><\/tr>
 <\/td>DIG_IT 2.0 – Roche<\/td>32.257,00<\/td>4,15%<\/td>3,15%<\/td><\/tr>
 <\/td>DIG_IT 2.0 – deferred income from 2021<\/td>32.258,50<\/td>4,15%<\/td>3,15%<\/td><\/tr>
 <\/td>GUIDE Asthma – Astra Zeneca<\/td>42.533,33<\/td>5,47%<\/td>4,15%<\/td><\/tr>
 <\/td>GUIDE Asthma – Chiesi<\/td>42.533,33<\/td>5,47%<\/td>4,15%<\/td><\/tr>
 <\/td>GUIDE Asthma – OM Pharma**<\/td>12.760,00<\/td>1,64%<\/td>1,25%<\/td><\/tr>
 <\/td>GUIDE Asthma – income deferred to 2023<\/td>-40.570,00<\/td>-5,22%<\/td>-3,96%<\/td><\/tr>
 <\/td>European Parliament Interest Group – Sanofi\/Regeneron<\/td>33.225,00<\/td>4,27%<\/td>3,25%<\/td><\/tr>
 <\/td>European Parliament Interest Group – deferred income from 2021<\/td>66.500,00<\/td>8,55%<\/td>6,50%<\/td><\/tr>
 <\/td>Deferred income 2022 to EFA Projects 2023<\/td>88.550,00<\/td> <\/td> <\/td><\/tr>
EU projects<\/td>78.755,07<\/td> <\/td> <\/td><\/tr>
 <\/td>CURE<\/td>36.048,97<\/td>45,77%<\/td>3,52%<\/td><\/tr>
 <\/td>3TR<\/td>8.333,29<\/td>10,58%<\/td>0,81%<\/td><\/tr>
 <\/td>Immuniverse<\/td>4.941,21<\/td>6,27%<\/td>0,48%<\/td><\/tr>
 <\/td>TOLIFE<\/td>7.811,40<\/td>9,92%<\/td>0,76%<\/td><\/tr>
 <\/td>SynAir-G<\/td>21.620,20<\/td>27,45%<\/td>2,11%<\/td><\/tr><\/tbody><\/table>\n","protected":false},"excerpt":{"rendered":"

EFA\u2019s total funding for 2022 was 1.023.846,19 EUR Euros: 90.89% was from corporate sources (unrestricted core- and project grants and honoraria for advisers) and 9.11% from non-corporate sources (membership fees and EU project grants). The highest contribution from a single source is 19,32%, amounting to the 197,786 Euros received from Chiesi Farmaceutici for the operating […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1096,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page_2022.php","meta":{"_acf_changed":false,"inline_featured_image":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"class_list":["post-604","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nTransparency & Acknowledgements - EFA - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transparency & Acknowledgements - EFA - Annual Report\" \/>\n<meta property=\"og:description\" content=\"EFA\u2019s total funding for 2022 was 1.023.846,19 EUR Euros: 90.89% was from corporate sources (unrestricted core- and project grants and honoraria for advisers) and 9.11% from non-corporate sources (membership fees and EU project grants). The highest contribution from a single source is 19,32%, amounting to the 197,786 Euros received from Chiesi Farmaceutici for the operating […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/\" \/>\n<meta property=\"og:site_name\" content=\"EFA - Annual Report\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/EFAPatients\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T13:40:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@EFA_Patients\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/transparency-acknowledgements\\\/\",\"url\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/transparency-acknowledgements\\\/\",\"name\":\"Transparency & Acknowledgements - EFA - Annual Report\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#website\"},\"datePublished\":\"2026-03-02T14:24:51+00:00\",\"dateModified\":\"2026-03-06T13:40:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/transparency-acknowledgements\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/transparency-acknowledgements\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/transparency-acknowledgements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022\",\"item\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022-2\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Financials\",\"item\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/2022\\\/financials\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Transparency & Acknowledgements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#website\",\"url\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/\",\"name\":\"EFA - Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#organization\",\"name\":\"EFA\",\"url\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/efanet.org\\\/annual-report\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/EFA_logo_OFFICIAL.webp\",\"contentUrl\":\"http:\\\/\\\/efanet.org\\\/annual-report\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/EFA_logo_OFFICIAL.webp\",\"width\":1341,\"height\":742,\"caption\":\"EFA\"},\"image\":{\"@id\":\"https:\\\/\\\/efanet.org\\\/annual-report\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/EFAPatients\",\"https:\\\/\\\/x.com\\\/EFA_Patients\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/efanet\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transparency & Acknowledgements - EFA - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/","og_locale":"en_GB","og_type":"article","og_title":"Transparency & Acknowledgements - EFA - Annual Report","og_description":"EFA\u2019s total funding for 2022 was 1.023.846,19 EUR Euros: 90.89% was from corporate sources (unrestricted core- and project grants and honoraria for advisers) and 9.11% from non-corporate sources (membership fees and EU project grants). The highest contribution from a single source is 19,32%, amounting to the 197,786 Euros received from Chiesi Farmaceutici for the operating […]","og_url":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/","og_site_name":"EFA - Annual Report","article_publisher":"https:\/\/www.facebook.com\/EFAPatients","article_modified_time":"2026-03-06T13:40:08+00:00","twitter_card":"summary_large_image","twitter_site":"@EFA_Patients","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/","url":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/","name":"Transparency & Acknowledgements - EFA - Annual Report","isPartOf":{"@id":"https:\/\/efanet.org\/annual-report\/#website"},"datePublished":"2026-03-02T14:24:51+00:00","dateModified":"2026-03-06T13:40:08+00:00","breadcrumb":{"@id":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/efanet.org\/annual-report\/2022\/financials\/transparency-acknowledgements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/efanet.org\/annual-report\/"},{"@type":"ListItem","position":2,"name":"2022","item":"https:\/\/efanet.org\/annual-report\/2022-2\/"},{"@type":"ListItem","position":3,"name":"Financials","item":"https:\/\/efanet.org\/annual-report\/2022\/financials\/"},{"@type":"ListItem","position":4,"name":"Transparency & Acknowledgements"}]},{"@type":"WebSite","@id":"https:\/\/efanet.org\/annual-report\/#website","url":"https:\/\/efanet.org\/annual-report\/","name":"EFA - Annual Report","description":"","publisher":{"@id":"https:\/\/efanet.org\/annual-report\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efanet.org\/annual-report\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/efanet.org\/annual-report\/#organization","name":"EFA","url":"https:\/\/efanet.org\/annual-report\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/efanet.org\/annual-report\/#\/schema\/logo\/image\/","url":"http:\/\/efanet.org\/annual-report\/wp-content\/uploads\/2025\/05\/EFA_logo_OFFICIAL.webp","contentUrl":"http:\/\/efanet.org\/annual-report\/wp-content\/uploads\/2025\/05\/EFA_logo_OFFICIAL.webp","width":1341,"height":742,"caption":"EFA"},"image":{"@id":"https:\/\/efanet.org\/annual-report\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFAPatients","https:\/\/x.com\/EFA_Patients","https:\/\/www.linkedin.com\/company\/efanet\/"]}]}},"coauthors":[],"author_meta":{"author_link":"https:\/\/efanet.org\/annual-report\/author\/quentin\/","display_name":"quentin"},"relative_dates":{"created":"Posted 2 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on 2 March 2026","modified":"Updated on 6 March 2026"},"absolute_dates_time":{"created":"Posted on 2 March 2026 14:24","modified":"Updated on 6 March 2026 13:40"},"featured_img_caption":"","featured_img":false,"series_order":"","_links":{"self":[{"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/pages\/604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/comments?post=604"}],"version-history":[{"count":1,"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/pages\/604\/revisions"}],"predecessor-version":[{"id":605,"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/pages\/604\/revisions\/605"}],"up":[{"embeddable":true,"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/pages\/1096"}],"wp:attachment":[{"href":"https:\/\/efanet.org\/annual-report\/wp-json\/wp\/v2\/media?parent=604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}